The Yunding Xinyao-B (01952) rose over 5% in the afternoon, as of the time of writing, up 5.80%, at HKD 21.9, with a turnover of 67.6309 million HKD.

On the news front, Yunding Xinyao previously released its interim results, with the group achieving a revenue of 0.302 billion yuan, a year-on-year increase of 3289.74%. The announcement stated that the increase in revenue was mainly due to the combined impact of Yijia's expanding sales in mainland China and Hong Kong, Nai Fu Kang's listing in mainland China and Singapore, and Nai Fu Kang's sales in other areas licensed by us.

Bocom intl released a research report stating that Yunding Xinyao's sales performance of new products in the first half of the year was excellent, with a month-on-month increase of 158% to 0.302 billion yuan, exceeding market expectations. The bank pointed out that after Nai Fu Kang was commercialized in mainland China in May, sales reached 0.167 billion yuan in just one and a half months. NMPA has accepted the supplementary application for complete approval of the product, and it is expected to be approved in 1H25. The future sales growth mainly comes from the promotion and education of guidelines, possible medical insurance negotiation access; Yijia sales reached 0.134 billion yuan, with a month-on-month increase of 35%. The subsequent growth is mainly driven by positive results in the real-world research of the National Health Commission, inclusion in multiple clinical guidelines, and deepening coverage in core markets.